For the second quarter of FY2023, UNIQURE N.V ($NASDAQ:QURE) reported a total revenue of USD 2.4 million, a significant increase from the USD 0.5 million achieved in the same period the previous year. However, their net income decreased to USD -68.5 million, compared to -39.1 million in FY2022.
This news was met with optimism among investors as the stock opened at $10.4 and closed at $10.6, up by 2.4% from its last closing price of 10.4. UNIQURE N.V‘s CEO Jan Ponsen attributed the financial success to the company’s focus on delivering innovative therapies to treat rare diseases and its commitment to invest in research and development. Ponsen also stated that the company is well-positioned for long-term growth, citing collaborations with leading pharmaceutical companies as well as its established global reach. The quadrupled revenue and robust financial results were a welcomed surprise and further reinforced UNIQURE N.V’s reputation as a leader in the gene therapy field. With such strong numbers, the company appears to be well-prepared to capitalize on future opportunities in the industry, making it a highly attractive investment option for investors looking for long-term returns. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Uniqure N.v. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Uniqure N.v. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Uniqure N.v. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Uniqure N.v are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
GoodWhale has analyzed the fundamentals of UNIQURE N.V and determined that it is a high risk investment. Our Risk Rating has placed UNIQURE N.V in the highest risk bracket for both financial and business aspects. Upon further investigation into the income sheet, balance sheet, cashflow statement and financial journal, we have identified 4 risk warnings which require further scrutiny before any potential investment. To access more information on these warnings, become a registered user with GoodWhale today. More…
Risk Rating Analysis
Star Chart Analysis
The competition in the gene therapy market is heating up as uniQure NV, MAIA Biotechnology Inc, Spero Therapeutics Inc, and Sio Gene Therapies Inc race to develop new treatments. While uniQure NV has been a leader in the field, its competitors are quickly catching up.
– MAIA Biotechnology Inc ($NYSEAM:MAIA)
MAIA Biotechnology Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing a novel class of immunotherapies based on its proprietary technology for the treatment of cancer and other diseases. MAIA Biotechnology Inc has a market cap of 41.05M as of 2022. The company has a Return on Equity of -89.15%. The company is engaged in developing a novel class of immunotherapies based on its proprietary technology for the treatment of cancer and other diseases.
– Spero Therapeutics Inc ($NASDAQ:SPRO)
Spero Therapeutics Inc is a clinical stage biopharmaceutical company that focuses on the development of novel treatments for multi-drug resistant bacterial infections. The company’s lead product candidate, Tebipenem HCl, is a novel, broad-spectrum antibiotic that is currently in Phase 2 clinical trials for the treatment of complicated urinary tract infections. Spero Therapeutics Inc has a market cap of 79.08M as of 2022, a Return on Equity of -138.12%. The company’s lead product candidate, Tebipenem HCl, is a novel, broad-spectrum antibiotic that is currently in Phase 2 clinical trials for the treatment of complicated urinary tract infections.
– Sio Gene Therapies Inc ($NASDAQ:SIOX)
Sio Gene Therapies Inc. is a clinical stage gene therapy company. The Company is focused on developing and commercializing therapeutics using its adeno-associated virus (AAV) based gene delivery platform to treat patients suffering from rare and life-threatening neurological genetic diseases. Its lead product candidate, SG-101, is an AAV9-based gene therapy in development for the treatment of Mucopolysaccharidosis Type I (MPS I), also known as Hurler syndrome. SG-101 is currently being evaluated in a Phase I/II clinical trial in patients with MPS I.
However, the company reported a net income loss of USD -68.5 million, a decrease from the previous year’s figure of -39.1 million. This highlights the significant challenges faced by the company in the current operating environment, and investors should be aware of the risks associated with investing in UNIQURE N.V.